about
De novo biosynthetic profiling of high abundance proteins in cystic fibrosis lung epithelial cells.Pharmacologic restoration of delta F508 CFTR-mediated chloride current.Cystic fibrosis presenting as recurrent pancreatitis in a young child with a normal sweat test and pancreas divisum: a case report.Applications of proteomic technologies for understanding the premature proteolysis of CFTR.Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial.Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate.Therapeutic approaches to repair defects in deltaF508 CFTR folding and cellular targeting.Direct interactions between ENaC gamma subunit and ClCN2 in cystic fibrosis epithelial cells.N-acetylcysteine enhances cystic fibrosis sputum penetration and airway gene transfer by highly compacted DNA nanoparticles.Analysis of ClC-2 channels as an alternative pathway for chloride conduction in cystic fibrosis airway cells.Levofloxacin pharmacokinetics in adult cystic fibrosis.Dual activation of CFTR and CLCN2 by lubiprostone in murine nasal epitheliaChemical rescue of deltaF508-CFTR mimics genetic repair in cystic fibrosis bronchial epithelial cells.Cystic fibrosis and estrogens: a perfect stormLubiprostone activates non-CFTR-dependent respiratory epithelial chloride secretion in cystic fibrosis mice.Respiratory epithelial gene expression in patients with mild and severe cystic fibrosis lung disease.The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles.Atypical cystic fibrosis and CFTR-related diseases.Current treatment recommendations for correcting vitamin D deficiency in pediatric patients with cystic fibrosis are inadequate.Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier.Transient effectiveness of vitamin D2 therapy in pediatric cystic fibrosis patients.Interference with ubiquitination in CFTR modifies stability of core glycosylated and cell surface pools.Cystic fibrosis and sinusitis in children: outcomes and socioeconomic status.CHOP transcription factor mediates IL-8 signaling in cystic fibrosis bronchial epithelial cells.Pharmacoproteomics of 4-phenylbutyrate-treated IB3-1 cystic fibrosis bronchial epithelial cells.Regulation of the ClC-2 lung epithelial chloride channel by glycosylation of SP1.Digitoxin for Airway Inflammation in Cystic Fibrosis: Preliminary Assessment of Safety, Pharmacokinetics, and Dose Finding.Protein processing and degradation in pulmonary health and disease.Modulation of Sp1 and Sp3 in lung epithelial cells regulates ClC-2 chloride channel expression.Effect of adeno-associated virus-specific immunoglobulin G in human amniotic fluid on gene transfer.Clinical Phenotypes and Genotypic Spectrum of Cystic Fibrosis in Chinese Children.Dietary supplement use in pediatric patients with cystic fibrosis.Protein microarray platforms for clinical proteomics.Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.A multicenter study of the effect of solution temperature on nasal potential difference measurements.A phase I trial of intranasal Moli1901 for cystic fibrosis.Modulation of deltaF508 cystic fibrosis transmembrane regulator trafficking and function with 4-phenylbutyrate and flavonoids.Can curcumin cure cystic fibrosis?Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis.Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis.
P50
Q33249392-79ABA83C-18A4-4B22-AEAA-609775885BE3Q33865177-5AAA143D-253F-4100-81D3-BBFD95543985Q34011874-4F22758E-E917-4B8C-A387-934EF47ED3CCQ34076025-67E4EA36-DB08-4E78-8139-A08A34EACE08Q34132007-843933E2-E9BF-4614-AABC-C23347C86193Q34136693-0055B83D-FBFA-4CB6-A0EA-FA1CD56E00AEQ35012417-74EA5710-2591-4079-842C-C224E0B1C91EQ35294275-B51791B3-EB58-4C1F-9327-6676F457C274Q35568532-2EAD6610-78E9-4598-A08B-6382CAC39A33Q36011771-C8526128-4B34-4521-A291-F06E950E52A5Q36137356-03A0A732-9A21-4856-9192-AFDD075EB054Q36699974-0B1686E9-C12D-4EB0-BF38-FAFE4C305BADQ36713641-D921916D-7223-4F47-8910-B9BB140073EEQ36972780-766C0BA9-F45D-4FCB-A17C-7D6A6FC764CBQ36977287-7C86BD63-3A8C-45B8-92C9-9B092EB2F7F6Q37098637-8EF6EA1C-B3A4-4591-9D5E-18D01F7C61E8Q37141909-7A1984E0-D4BE-434F-AFE9-BB1411365FACQ37169176-633519B9-5110-4A74-8594-CF5D73A04858Q37203150-9A29343D-420D-45FC-BC79-56780B87EE30Q37429043-C0DA1E9F-9F4F-46D8-ADCD-C3F2B3B553BCQ37684308-B85A8DE2-E390-47B4-8C13-85A2C9A66E59Q39000578-81A11DB0-0F7B-4342-AAB2-00A32AF6C378Q39979237-A7EC50DC-88F6-4E58-88E6-D90831030755Q40091288-94BCF551-9777-4BDB-8811-8605C31B76E0Q40309578-AF91F54B-AFAC-4431-B004-08ADB4E2AB43Q40321086-A55FC47E-2EC4-492E-8BF5-5F52CE1064CFQ40398640-EE6718D9-9B9D-445B-8372-F1D597C3A0AAQ40554835-C5868152-1D6E-44FF-9247-FBF51E6EC514Q40652287-C23E1A8C-1461-405A-BAD4-6ECA22224695Q40661268-92243914-6F0E-40D2-95EB-F2487FABFE8AQ40940768-589DB43B-EEC5-4DE5-B7F0-0E1DD4BF717CQ42647357-D15BE6BB-0AED-463D-89A9-4A0BF86EBAA4Q42784880-0FDDA78F-8FC8-4E9C-8E45-6F40CDE5D292Q44248035-52B412D0-E62B-4E0B-BD48-9AFC9C897017Q44542274-1A58529A-6A2C-4EA6-B2FB-BAA0136968AAQ44725248-75C34E56-B0D7-44EC-AC46-EADC9CDAC53FQ44932422-A73B5EE7-7ECC-4993-8A59-979765855272Q45007611-42D5D9C7-FC2C-4BEB-8119-C624E50C9735Q45198841-832412AF-71EC-4ED2-81D8-EC59A4C49833Q45259943-2BE4F438-1ADE-49EB-8D6C-716AF8C4DA43
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Pamela Zeitlin
@ast
Pamela Zeitlin
@en
Pamela Zeitlin
@es
Pamela Zeitlin
@nl
Pamela Zeitlin
@sl
type
label
Pamela Zeitlin
@ast
Pamela Zeitlin
@en
Pamela Zeitlin
@es
Pamela Zeitlin
@nl
Pamela Zeitlin
@sl
prefLabel
Pamela Zeitlin
@ast
Pamela Zeitlin
@en
Pamela Zeitlin
@es
Pamela Zeitlin
@nl
Pamela Zeitlin
@sl
P106
P1153
7004500644
P21
P31
P496
0000-0002-2719-1834